RxDoctor Payments Data

Rebecca Nash

Family · Chilhowie, VANPI 1649668831

Payments from drug & device makers

$2,493in general payments, 2019–2025

Across 148 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$530
  • AstraZeneca$221
  • Pfizer$221
  • AbbVie$151
  • Abbott$131
  • GSK$130
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,493 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$79,317
OzempicSemaglutide63$62,155
TrulicityDulaglutide20$32,212
RybelsusSemaglutide24$32,171
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$23,231
JardianceEmpagliflozin16$18,471
FarxigaDapagliflozin Propanediol24$16,002
XareltoRivaroxaban23$14,123
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$13,431
MounjaroTirzepatide12$12,705
Tresiba Flextouch U-100Insulin Degludec21$8,436
Tresiba Flextouch U-200Insulin Degludec13$7,981
Breo ElliptaFluticasone/Vilanterol14$5,414
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,937
Humalog Kwikpen U-100Insulin Lispro19$3,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$530$94,32687 claims
PfizerEliquis$221$79,31782 claims
Lilly USA, LLCTrulicity, Mounjaro$111$44,91732 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$130$42,07673 claims
Boehringer IngelheimJardiance$130$18,47116 claims
AstraZenecaFarxiga$221$16,00224 claims
Johnson & JohnsonXarelto$13$14,12323 claims
AbbVieSynthroid$151$3,14356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Chilhowie

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →